OncoMatch/Clinical Trials/NCT07060807
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Is NCT07060807 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for breast neoplasms.
Treatment: Patritumab deruxtecan · Paclitaxel · Nab-paclitaxel · Capecitabine · Liposomal doxorubicin · Trastuzumab deruxtecan — Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2 * Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles * Metastatic means the cancer has spread to other parts of the body Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive
Has centrally-confirmed HR+ and HER2- results
Required: HER2 (ERBB2) negative
Has centrally-confirmed HR+ and HER2- results
Required: ERBB3 evaluable
human epidermal growth factor receptor 3 (HER3) evaluable results from a biopsy
Excluded: BRCA1 deleterious or suspected deleterious germline mutation
Has a known germline breast cancer gene (BRCA) mutation (deleterious or suspected deleterious) where poly (ADP-ribose) polymerase (PARP) inhibitor(s) is a potential treatment option
Excluded: BRCA2 deleterious or suspected deleterious germline mutation
Has a known germline breast cancer gene (BRCA) mutation (deleterious or suspected deleterious) where poly (ADP-ribose) polymerase (PARP) inhibitor(s) is a potential treatment option
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: CDK4/6 inhibitor + endocrine therapy — advanced or adjuvant
Must have had progression or recurrence on prior cyclin-dependent kinase (CDK)4/6 inhibitor + endocrine therapy (ET)
Cannot have received: chemotherapy
Exception: for unresectable locally advanced or metastatic breast cancer
Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer
Cannot have received: anti-HER3 antibody
Has received prior treatment with an anti-HER3 antibody
Cannot have received: antibody-drug conjugate that consists of a topoisomerase I inhibitor (T-DXd)
Has received prior treatment with ... antibody-drug conjugate that consists of a topoisomerase I inhibitor (eg, T-DXd) or any other topoisomerase I inhibitor therapy
Cannot have received: topoisomerase I inhibitor
Has received prior treatment with ... any other topoisomerase I inhibitor therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Southern Cancer Center (SCC) ( Site 8000) · Daphne, Alabama
- Los Angeles Hematology Oncology Medical Group ( Site 0026) · Los Angeles, California
- Hoag Memorial Hospital Presbyterian ( Site 0025) · Newport Beach, California
- St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021) · Grand Junction, Colorado
- Medical Oncology Hematology Consultants (MOHC) ( Site 8002) · Newark, Delaware
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify